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esponsibility of Xi’Abstract Three extraction methods were compared for their efﬁciency to analyze sitagliptin and
simvastatin in rat plasma by LC–MS/MS, including (1) liquid–liquid extraction (LLE), (2) solid phase
extraction (SPE) and (3) supported liquid extraction (SLE). Comparison of recoveries of analytes with
different extraction methods revealed that SLE was the best extraction method. The detection was
facilitated with ion trap-mass spectrometer by multiple reactions monitoring (MRM) in a positive ion
mode with ESI. The transitions monitored were m/z 441.1-325.2 for simvastatin, 408.2-235.1 for
sitagliptin and 278.1-260.1 for the IS. The lower limit of quantiﬁcation (LLOQ) was 0.2 ng/mL for
sitagliptin and 0.1 ng/mL for simvastatin. The effective SLE offers enhanced chromatographic selectivity,
thus facilitating the potential utility of the method for routine analysis of biological samples along with
pharmacokinetic studies.
& 2015 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Sitagliptin and simvastatin combination (Fig. 1) is used together
with a proper diet and exercise to treat type 2 diabetes (T2D).ity. Production and hosting by Elsevie
rg/licenses/by-nc-nd/3.0/).
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(P.S. Devi).
an Jiaotong University.Patients with T2D are at risk of vascular complications including
cardiovascular disease [1–3], and therapy with statins in this
population is widely recommended [4,5]. The combination of
sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor which
improves glycemic control [6,7], and simvastatin, a well char-
acterized lipid-lowering agent [8], may be considered an appro-
priate approach to management of this disease [4–9]. Recently, the
US Food and Drug Administration (FDA) has approved sitagliptinr B.V. All rights reserved. This is an open access article under the CC BY-
Fig. 1 Chemical structures of (A) sitagliptin, (B) simvastatin and (C) venlafaxine HCl (IS).
B. Ramesh et al.162and simvastatin (JuvisyncW, Merck Sharp & Dohme Corp., NJ,
USA) [10], a ﬁxed-dose combination prescription medication that
contains two previously approved medications in a single tablet for
use by adults who need both sitagliptin and simvastatin. Juvisync
was approved in dosage strengths for sitagliptin/simvastatin of
100/10 mg, 100/20 mg and 100/40 mg.
Sample preparation is an important step in the biopharmaceu-
tical analysis process because of the difﬁculties that follow with
complex sample matrices, e.g. plasma and urine. Sample pre-
paration typically takes 80% of the total analysis time [11]. Solid
phase extraction (SPE) and liquid–liquid extraction (LLE) are
among the most commonly used sample preparation methods for
biological sample analysis. SPE is a time-consuming extraction
for method development and sample analysis, even though it is
feasible for automation. LLE requires a large volume of organic
solvent that is harmful to human health and usually needs a large
number of specimens. Furthermore, emulsiﬁcation occurs too
frequently during the extraction; thus, repeatability is not
satisfactory. SLE is a promising sample cleanup technology that
is particularly suitable for the 96-well format operation. Similar
to the traditional LLE, SLE provides very clean extracts with a
high recovery.
Several analytical methods, available in the literature, include
tandem mass spectrometry method, liquid chromatography and gas
chromatography–mass spectrometry (GC–MS) methods for the
determination of sitagliptin alone or in combination with other
drugs in biological samples [12–20]. Other methods are also
available for the determination of simvastatin in other drugs in
biological samples or in their individual form [21–32]. However,
Burugula et al. [33] developed an LC–MS/MS for the analysis of
sitagliptin and simvastatin in human plasma, which employed LLE
with a total run time of 3.0 min for each sample.
The present communication detailed our attempts to develop and
validate a reliable bioanalytical method for simultaneous determina-
tion of sitagliptin and simvastatin in rat plasma by ion trap LC–MS/
MS using SLE. A direct comparison of SLE with traditional
extraction techniques, namely LLE and SPE, will demonstrate the
preserved analytical advantages of this new method, with the beneﬁt
of increased sample throughput. SLE is similar to LLE but differs
from it in that the sample is totally absorbed onto a solid phase,
containing a modiﬁed form of diatomaceous earth, on which the
extraction occurs. The retention time of sitagliptin, simvastatin and
the IS was as low as 0.81, 1.31 and 1.62 min, facilitating a short run
time of 2.0 min. Improved experimental conditions facilitated a
rapid, simple and sensitive LC–MS/MS method for simultaneous
determination of sitagliptin and simvastatin in rat plasma, with a
very characteristic separation pattern and enhanced chromatographic
selectivity. The potential utility of the method has been thoroughly
enhanced, where subtle but distinguishable separations with verylow analytical run times were accomplished with Oyster ODS3
column. Herein, we present the experimental conditions and the
application of the same for pharmacokinetic studies and bioanaly-
tical evaluation.2. Experimental
2.1. Materials and reagents
The reference samples of sitagliptin (purity 499.30%) and simvas-
tatin (purity 499.82%) were kind gift from Sipra labs (Hyderabad,
India) whereas venlafaxine hydrochloride (purity499.25) was
obtained from Micro Labs Ltd. (Bangalore, India). Water used for
the LC–MS/MS analysis was prepared using a Synergy Milli Q water
puriﬁcation system. HPLC-grade acetonitrile, methanol and acetic
acid, formic acid and methyl tert-butyl ether (MTBE) were purchased
from Merck Ltd. (Mumbai, India). Ammonium acetate and ammo-
nium formate were supplied by Qualigens Pvt. Ltd. (Bangalore,
India). Sample tubes were obtained from Tarsons Pvt. Ltd. (Kolkata,
India). For SLE extraction, SLEþ, 1 mL supported liquid extraction
columns (Biotage, Uppsala, Sweden) were used. Freshly obtained
drug-free rat plasma was collected from male Wistar rats in our
laboratory and stored at 80 1C prior to use.
2.2. LC–MS/MS analysis
Chromatographic separation was performed on an Oyster ODS3
(4.6 mm 50 mm, 3 mm) column using the isocratic mode of
elution. LC–MS/MS studies were performed using an Agilent
1100 MSD ion-trap-SL mass spectrometer with electrospray ioni-
zation (ESI) source in positive ion mode equipped with a degasser
(G1379A), binary pump (G1312A), autosampler (G1329A), auto-
sampler thermostat (G1329B) and diode array detector (G1315B).
The data were acquired and processed using Chemstation 5.3
(Agilent Technologies, Waldbronn, Germany). An isocratic elution
with acetonitrile: 5 mM ammonium acetate buffer (pH 4.570.05)
(85:15, v/v) as mobile phase was pumped at a ﬂow rate of
0.75 mL/min; the sample injection volume was 20 mL with column
temperature maintained at ambient conditions. At a time when
most of the contemporary work from other laboratories was carried
out using either a single or triple quadruple instruments, in the
present work, an ion trap mass spectrometric analysis was
deliberately employed because this mode also facilitated excellent
analytically quantitative and mass selective resolutions [34] even
for compounds structurally unrelated to diverse physicochemical
properties. The sensitivity of the multiple reaction monitoring
(MRM) was optimized by testing with an infusion of 0.1 μg/mL
each of analytes and IS in mobile phase. Detection of the ions was
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z 408.2–235.1 for sitagliptin, m/z 441.1–325.2 for simvastatin and
m/z 278.1–260.1 for the IS. Nitrogen was employed as the
nebulizer and curtain gas. Collision-induced dissociation was
achieved using helium as collision gas. The ion source conditions
were set as follows: temperature, 335 1C; nebulizer gas, 35 psi; dry
gas, 10.0 L/min; skimmer, 40.0 V; capillary exit, 128.0 V; trap
drive, 44.5; maximum accumulation time, 200 ms; and Icc target,
20,000.
2.3. Preparation of standard and quality control (QC) samples
Calibration standards were prepared by spiking the working
standard solution into a pool of drug-free rat plasma in order to
obtain the following concentrations: 0.2, 0.4, 5.0, 30, 60, 120, 200,
275, 350 and 450 ng/mL of sitagliptin and 0.1, 0.2, 5.0, 10, 20, 50,
100, 250, 350 and 450 ng/mL of simvastatin. The concentrations
of QC samples of sitagliptin and simvastatin were as follows: 0.3
(quality control sample at low concentration, LQC), 150 (quality
control sample at medium concentration, MQC), and 400 (quality
control sample at high concentration, HQC) ng/mL and 0.15
(LQC), 150 (MQC) and 400 (HQC) ng/mL in blank plasma. The
spiked samples were then treated as described in sample prepara-
tion. All the samples were stored at 80 1C.
2.4. Sample preparation methods
2.4.1. LLE
LLE was carried out by the procedure described by Burugula et al.
[33]. A 200 mL aliquot of rat plasma sample was mixed with 50 mL
of the IS working solution (50 ng/mL). To this, 100 mL of
100 mM ammonium acetate buffer (pH 4.570.05) was added.
After overtaxing for 15 s, a 4 mL aliquot of the extraction solvent
(MTBE and n-hexane, 70:30, v/v) was added and the sample was
vortexed for 30 s and then centrifuged for 5 min at 4000 rpm. The
organic layer was transferred to a 10 mL glass test tube and
evaporated at 40 1C under a stream of nitrogen. The dried extract
was reconstituted in 250 mL of the mobile phase and transferred
into auto-injector vials and 20 mL aliquot was injected into the
chromatographic system.
2.4.2. SPE
A 200 mL aliquot of rat plasma sample was mixed with 50 μL of
the working solution of IS (50 ng/mL) followed by 500 mL of
water, and the contents were mixed by vortex for 10 s and
subjected to SPE. The sample mixture was loaded onto a StrataX
33 μm polymeric sorbent cartridge (100 mg/3 mL) that was pre-
conditioned with 2.0 mL of methanol followed by 2.0 mL Milli Q
water. Washing of cartridges was performed with 2 mL of 20%
methanol in water.
Analytes and IS were eluted with 2.0 mL of the mobile phase.
An aliquot of 20 μL of the sample was injected into the LC–MS/
MS system for analysis.
2.4.3. SLE
A 200 mL aliquot of sample was diluted with 50 μL of the IS
solution (50 ng/mL) followed by 300 mL of 5 mM ammonium
acetate buffer (pH 4.570.05) and then mixed for 10 s and loaded
onto an Isolute SLEþ cartridge. A minimum positive pressure was
applied to facilitate the sample absorption into the cartridge in less
than 10 s. After the analytes were allowed to equilibrate with thesorbent for a minimum of 5 min, the compounds were eluted with
an aliquot of 1 mL of extraction solvent. The extraction solvent
was eluted by applying a little positive pressure from the top with
a rubber bulb for fast elution and evaporated to dryness under a
stream of heated nitrogen at 40 1C. Finally the residues were
reconstituted in 400 mL methanol solution (aq) and vortexed at
medium speed for approximately 1 min.
A 20 mL aliquot of the reconstituted solution was injected into
the LC–MS/MS system for analysis.3. Results and discussion
3.1. Method development
To develop a sensitive and reliable LC–ESI–MS/MS method, it
is important to optimize the chromatographic and mass spectro-
metric conditions, as well as to obtain an efﬁcient and simple
extraction procedure for all the analytes along with a suitable
IS. Choosing the appropriate IS is an important aspect to
achieve acceptable method performance, especially with LC–
MS/MS, where matrix effects can lead to poor analytical results.
In the present method, several compounds were investigated to
ﬁnd a suitable IS, and ﬁnally venlafaxine hydrochloride was
chosen because it offers high recovery, less analytical run time
and does not hamper the employed analytical evaluation at any
stage of analysis.3.2. Optimization of chromatography
In the present work, chromatography was performed on several
reversed-phase columns like Agilent Zorbax C8 (4.6 mm 150
mm, 5 μm), Xterra RP C18 (4.6 mm 250 mm, 5 mm), XDB–C18
(4.6 mm 150 mm, 5 mm), Oyster C8 (4.6 mm 50 mm, 5 mm),
Oyster ODS3 C18 (4.6 mm 50 mm, 3 mm), Atlantis dC18
(4.6 mm 150 mm, 5 mm), and SUPELCO Discovery C8
(4.6 mm 250 mm, 5 mm) to achieve a short run time, symmetric
peak shapes, minimum matrix interference and solvent consump-
tion. This was investigated by appropriate changes to mobile phase
composition (aqueous and organic part), buffer pH and ﬂow rate.
Thus to arrive at an ideal solvent system, we attempted various
combinations of methanol/acetonitrile along with buffers (ammo-
nium formate/formic acid, ammonium acetate/acetic acid, ammo-
nium acetate/ammonia) having different ionic strengths (1–
10 mM) in the pH range of 3.0–8.0 and volume ratios (60:40,
70:30, 80:20, 85:15 and 90:10, v/v). Further, the effect of ﬂow rate
was also studied from 0.6 to 1.2 mL/min, which was always
considered to be responsible for acceptable chromatographic
resolution. Use of a 5 mM ammonium acetate buffer (pH
4.570.05) helped in achieving a good response for MS detection
in the positive ionization mode for both the analytes and the IS. It
was found that a mixture of acetonitrile and 5 mM ammonium
acetate buffer (pH 4.570.05; 85:15, v/v) could achieve this
purpose and was ﬁnally employed as the suitable mobile phase.
An Oyster ODS3 column facilitated well peak shape and response
even at the lowest concentration level for both the analytes and IS
(Fig. 2E). The mobile phase was operated at a ﬂow rate of
0.75 mL/min. The retention time of sitagliptin, simvastatin and the
IS was low enough to be 0.81, 1.31 and 1.62 min, respectively,
allowing a short run time of 2.0 min.
Fig. 2 Typical chromatograms of analytes (a¼sitagliptin,
b¼simvastatin and c¼ IS) acquired at different columns to evaluate
peak resolution. (A): Agilent Zorbax C8 (4.6 mm  150 mm, 5 mm);
(B): Xterra RP C18 (4.6 mm 250 mm, 5 mm); (C): XDB–C18
(4.6 mm 150 mm, 5 mm); (D): Oyster C8 (4.6 mm 50 mm,
5 mm); (E): Oyster ODS3 C18 (4.6 mm 50 mm, 3 mm); (F): Atlantis
dC18 (4.6 mm 150 mm, 5 mm); and (G): SUPELCO Discovery C8
(4.6 mm 250 mm, 5 mm).
Fig. 3 Full scan product ion of precursor ions of sitagliptin,
simvastatin and IS.
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As both the analytes have very different structures and ionization
behavior, the tuning of mass parameters was carried out using ESI
in positive. Standard solutions of the analytes and IS were directly
infused along with the mobile phase into the mass spectrometer
with ESI as the ionization source. LC–MRM is a very powerful
technique for pharmacokinetic studies since it efﬁciently offers
greater sensitivity and selectivity for any analytical method
employed and thus the MRM technique was chosen for the assay
development. The MRM parameters were optimized to maximize
the response for the analyte. The most sensitive mass transition
was monitored from m/z 408.2 to 235.1 for sitagliptin, from m/z
441.1 to 325.2 for simvastatin and from m/z 278.1 to 260.1 for the
IS. The product ions of these compounds are shown in Fig. 3.3.4. Optimization of sample preparation
In our studies, different extraction methods such as LLE, SPE and
SLE were studied and compared. LLE with mixture of MTBE and
n-hexane (70:30, vv), SPE with StrataX 33 μm polymeric sorbent
cartridge (100 mg/3 mL) and SLE with Isolute SLEþ cartridge
were investigated during the method development. As shown in
Fig. 4A, the extraction efﬁciencies for sitagliptin and simvastatinwere improved signiﬁcantly with SLE. Therefore, SLE was
employed to treat the sample. The parameters evaluated in method
development were extraction solvent, recovery of analytes after
evaporation and reconstitution of the samples, and plasma volume
to be extracted. For sample elution, a number of organic solvents
were investigated for SLE experiments. These were ethyl acetate,
diethyl ether, MTBE, iso-propanol and dichloromethane. Finally,
ethyl acetate was found to give cleaner extract and higher recovery
(Fig. 4B). The recoveries of analytes were studied after evapora-
tion and reconstitution in aqueous methanol solutions of various
strengths (90%, 80% and 70%). Finally, a solution consisting of
90% methanol (aq) was chosen for reconstitution of the samples.
Here, a combination of 200, 300, 400 and 500 mL diluent and 200,
300, 400 and 500 mL of plasma was also investigated. We found
that 200 mL plasma and 400 mL diluent improved the extraction
recovery.
3.5. Method validation
The validation process was carried out according to Guidance for
Industry–Bioanalytical Method Validation recommended by U.S.
Food and Drug Administration [35]. The method was validated for
Fig. 4 (A) Comparison of sample cleanup methods and (B)
comparison of various extraction solvents.
Fig. 5 Representative MRM ion-chromatograms of (A) blank plasma
and (B) blank plasma spiked with IS at 50 ng/mL, (C) simvastatin at
0.05 ng/mL (LLOQ), (D) sitagliptin at 0.1 ng/mL (LLOQ), (E)
simvastatin and (F) sitagliptin in rat plasma sample collected at
120 min after oral administration.
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recovery, matrix effect, carryover and stability.
3.5.1. Selectivity
Selectivity of the method was evaluated by analyzing six
different blank plasma samples to investigate the potential
interferences at the LC retention time for the analytes and IS.
The selectivity of the method was tested by comparing the
chromatograms of blank plasma and the spiked plasma. Under
the above conditions, the retention time of sitagliptin, simvas-
tatin and IS was 0.81, 1.31 and 1.62 min, respectively. All
plasma lots were found to be free of interferences with the
compounds of interest. As shown in Fig. 5, there was no
interference at the retention time of sitagliptin, simvastatin
and IS.
3.5.2. Calibration curves
To prepare the standard curves, appropriate amounts of
sitagliptin and simvastatin were added to blank plasma yield-
ing the following concentrations: 0.1, 0.2, 0.4, 5.0, 30, 60,120, 200, 275, 350 and 450 ng/mL for sitagliptin and 0.05, 0.1,
0.2, 5.0, 10, 20, 50, 100, 250, 350 and 450 ng/mL for
simvastatin. These samples were then prepared in triplicate
according to the procedure described above. The calibration
curve was found to be linear over the concentration range of
0.10–450 ng/mL for sitagliptin and 0.05–450 ng/mL for sim-
vastatin. The calibration curve was constructed by plotting the
peak area ratio of analyte to IS vs the nominal concentration in
plasma. The data were subjected to statistical analysis using a
linear regression model, showing that the regression equation
was y¼0.002xþ0.047, with correlation coefﬁcient (R2) greater
than 0.996 for sitagliptin and y¼0.044xþ0.112, with correla-
tion coefﬁcient (R2) greater than 0.998 for simvastatin, where y
represents the peak area ratio of analytes to that of IS and x
represents the concentration of analytes in ng/mL.3.5.3. Precision and accuracy
The intra-day assay precision and accuracy were obtained by
analyzing six replicates of LLOQ and QC samples on a single day.
The inter-day assay precision and accuracy were obtained by
analyzing six replicates of LLOQ and QC samples on 3 different
days. Intra-day and inter-day precisions of the method were
expressed by [standard deviation/mean concentration] 100%.
Accuracy of the method was expressed by [(mean measured
concentration–nominal concentration)/nominal concentration] 100%.
The relative percentage error (RE%) of the mean value should be
within 715% at each concentration except for the LLOQ, where the
RE should be within 720%. The precision was required to be less
than 20% at the LLOQ level and less than 15% at other concentrations.
As shown in Table 1, the values for both intra- and inter-day accuracy
and precision were found to be within the acceptable criteria.
Table 1 Intra-and inter-day precision and accuracy for the detection of sitagliptin and simvastatin in rat plasma (n¼6).
Analyte Conc.
added
(ng/mL)
Intra-day Inter-day
Conc. found
(ng/mL)
Precision
(RSD, %)
Accuracy
(RE, %)
Conc. found
(ng/mL)
Precision
(RSD, %)
Accuracy
(RE, %)
(mean7SD) (mean7SD)
Sitagliptin 0.2 0.2170.02 10.2 5.1 0.2170.02 9.6 5.2
0.6 0.5670.04 6.7 6.6 0.6370.03 8.0 5.1
150 15472.9 1.9 2.6 15273.2 2.1 2.0
400 39875.6 1.4 0.5 40474.3 1.1 1.1
Simvastatin 0.1 0.1170.01 9.2 10.1 0.0970.01 10.4 2.1
0.5 0.5470.04 6.2 8.1 0.5170.02 4.0 2.1
150 15272.7 1.8 1.4 15572.1 1.4 3.3
400 40576.1 1.5 1.2 40273.1 0.8 0.5
Table 2 The recovery and matrix effect of sitagliptin, simvastatin and IS (n¼6).
Analyte Concentration (ng/mL) Recovery (%) Matrix effect (%)
Mean7SD RSD Mean7SD RSD
Sitagliptin 0.6 71.172.5 3.5 90.172.5 2.8
150 74.472.2 2.9 94.674.0 4.3
400 77.171.3 1.7 96.873.5 3.7
Simvastatin 0.5 82.273.2 3.9 91.671.9 2.1
150 81.672.9 3.5 92.273.9 4.2
400 78.272.6 3.3 95.174.5 4.8
IS 50 75.171.8 2.4 93.273.9 4.2
Table 3 Stability of sitagliptin and simvastatin in rat plasma (n¼6).
Stability tested Sitagliptin Simvastatin
Conc. added
(ng/mL)
Conc. found
(ng/mL)
Precision
(RSD, %)
Accuracy
(RE, %)
Conc. added
(ng/mL)
Conc. found
(ng/mL)
Precision
(RSD, %)
Accuracy
(RE, %)
Autosampler stability
(at 10 1C for 24 h)
0.6 0.5870.02 3.4 3.3 0.5 0.4970.04 8.7 2.0
400 40575.20 1.9 1.2 400 40273.0 0.7 0.5
Bench-top stability
(4 h at room temperature)
0.6 0.5970.05 8.5 1.7 0.5 0.5370.03 5.7 6.0
400 40373.60 0.9 0.7 400 40374.20 1.0 0.7
Freeze–thaw stability
(three cycles)
0.6 0.6370.04 6.3 5.0 0.5 0.5270.02 3.8 4.0
400 40472.90 0.7 1.0 400 40673.60 0.9 1.5
Long-term stability
(at 70 1C for 60 days)
0.6 0.6470.03 4.7 6.6 0.5 0.5470.03 5.5 8.0
400 40374.20 1.0 0.7 400 40473.80 1.0 1.0
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The extraction recovery for each analyte for three levels of QC
samples was assessed by comparing the peak areas for extracted
spiked plasma samples with the peak areas for pure compounds of
the same concentrations in solvent. The recovery of the IS was
evaluated at the concentration used in sample analysis. Matrix
effect was investigated to ensure precision, selectivity and
sensitivity that were not compromised by the matrix screened.Blank biological samples were extracted and then spiked with the
analytes at three QC levels and IS in ﬁve replicates. The
corresponding peak areas were compared with those of standard
solutions, and the peak area ratio was deﬁned as the matrix effect.
Table 2 shows the results of the recovery and the matrix effect for
sitagliptin, simvastatin and IS. The results indicated satisfactory
recovery and no signiﬁcant relative matrix effect, which could
negatively inﬂuence quantitation results.
LC–ESI–MS/MS analysis of sitagliptin and simvastatin in plasma 1673.5.5. Carryover
The carryover was evaluated by analyzing a blank sample
immediately after the upper limit of quantiﬁcation (ULOQ) sample
of the standard curve. The carryover level should beo20% of the
response observed for the analyte at LLOQ and o5% of the
response observed for the IS at the working concentration. No
peak was observed at the retention time of any analyte or IS in the
chromatogram of a blank sample analyzed after the injection of
ULOQ sample, indicating the absence of carryover.3.5.6. Stability
The stability tests of the analytes were designed to cover expected
conditions concerning the handling of clinical samples. The stabilities
of sitagliptin and simvastatin in plasma at different concentrations were
examined under different study conditions, i.e. keeping at room
temperature for 4 h (bench–top stability) and storing at 70 1C for
at least 2 months (long-term stability). The stabilities of sitagliptin and
simvastatin in plasma extracts were also tested by keeping the samples
at 10 1C for 24 h (autosampler stability). Freeze/thaw stability was
determined after freezing (30 1C) and thawing for three cycles. All
the stability studies were conducted at LQC and HQC levels using six
replicates at each level. Samples were considered to be stable if assay
values were within the acceptable limits of accuracy (r15% RE) and
precision (r15% RSD). The results are summarized in Table 3. TheFig. 6 Mean plasma concentration–time proﬁles of sitagliptin and
simvastatin after administration to rats (n¼5).
Table 4 Main pharmacokinetic parameters of sitagliptin and simvas
Pharmacokinetic parameters Sitagliptin (m
Cmax (ng/mL) 5173
Tmax (h) 1.0
t1/2 (h) 6.170.2
AUC0 t (ng h/mL) 320715
AUC01 (ng h/mL) 323716
MRT01 (h) 7.470.3results indicated that sitagliptin and simvastatin were stable for the
entire period of the experiment.3.6. Application of the method to a pharmacokinetic study
The applicability of the developed bioanalytical method (SLE–LC–
ESI/MS) for sitagliptin and simvastatin in rat plasma was demonstrated
by the results obtained from pharmacokinetic studies conducted in
three male Wistar rats weighing 250710 g approximately, which were
fasted overnight before and 4 h after dosing. (The study was approved
by the Animal Ethical Committee of Indian Institute of Chemical
Technology, Hyderabad.) Each rat received an oral dose of 15 mg/kg
sitagliptin and 25 mg/kg of simvastatin in gum acacia suspension.
Blood samples were collected from orbital sinus into EDTA coated
tubes at 0, 0.5, 0.75, 1, 1.25, 1.50, 3, 6, 12, 24 and 48 h time intervals
after drug administration. The blood samples were centrifuged at
5000 rpm for 10 min and the plasma samples were stored at 80 1C
until analysis. The samples were determined by the chromatographic
conditions described as in Section 2.2. Plasma drug concentration–time
data were subjected to noncompartmental pharmacokinetic analysis
using linear trapezoidal rule. Fig. 6 shows the mean plasma concentra-
tion–time proﬁle of sitagliptin and simvastatin. The pharmacokinetic
parameters such as Cmax, Tmax, t1/2, AUC0 t, AUC01 and MRT for
sitagliptin and simvastatin are summarized in Table 4.4. Conclusion
A simple, rapid and sensitive LC–MS/MS method was developed
and validated for the simultaneous determination of sitagliptin and
simvastatin in rat plasma with simple SLE method in a very short
run time of 2 min. The present SLE method has the highest
recovery compared with other extraction with techniques. The
validation study successfully evaluated intra-day and inter-day
precision, selectivity, sensitivity, linearity, recovery, carryover,
matrix effect and sample stability. The results of the rat plasma
validation parameters were well within the acceptable limits.
Further, the plasma matrix components do not interfere with the
analysis. The LLOQ was 0.2 ng/mL for sitagliptin and 0.1 ng/mL
for simvastatin, using 100 mL of plasma sample. The method
offers signiﬁcant advantages over those previously reported, in
terms of improved sensitivity, requiring a small volume of
extraction solvent, simplicity of extraction procedure and short
overall analytical run time. The efﬁciency of SLE and chromato-
graphic run time of 2.0 min per sample render the method useful in
high-throughput bioanalysis. The fully validated method is simple,
highly sensitive, speciﬁc, robust, and has been successfully applied
to pharmacokinetic study in rats. This method is suitable for
routine analysis of a large number of biological samples.tatin in rat plasma (n¼6).
ean7SD) Simvastatin (mean7SD)
204712
0.75
5.670.1
982730
987729
6.370.3
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